High Potency APIs Market/HPAPI Market

Market Leadership - High Potency APIs/HPAPI Market

The HPAPI market is projected to reach USD 39.6 Billion by 2027 from USD 24.5 billion in 2022, at a CAGR of 10.1% from 2022 to 2027. The growth in this market is driven by factors such as increasing demand for oncology drugs, growing demand for antibody-drug conjugates, increasing focus of leading pharmaceutical companies on HPAPIs, advancements in HPAPI manufacturing technologies, and growing focus on precision medicine.

The major players in the High Potency APIs Market include Pfizer Inc. (US), Novartis International AG (Switzerland), Merck & Co. (US), Teva Pharmaceutical Industries Ltd. (Israel), Viatris Inc. (US), Boehringer Ingelheim (Germany), Sanofi (France), AbbVie (US), Eli Lilly and Company (US), and Bristol-Myers Squibb (US). Various growth strategies have been adopted by these players, such as agreements, collaborations, partnerships, and acquisitions to increase their presence in the global human microbiome market.

To know about the assumptions considered for the study download the pdf brochure

Pfizer held the leading position in the HPAPI market in 2021. The dominant position of the company is primarily attributed to its exhaustive product portfolio. The company has been operating in the HPAPI market for more than a decade and has a strong brand image, which gives it a competitive edge over other players. To remain competitive and strengthen its market position, the company primarily focuses on adopting both organic and inorganic growth strategies such as acquisitions and expansions. Over the past few years, Pfizer acquired Arena Pharmaceuticals (US), Anacor Pharmaceuticals (US), and Hospira (US). Such acquisitions enabled the company to expand its product offerings and global market presence.

R&D Capabilities: Pfizer’s growth strategy is driven by five “Bold Moves” that help the company deliver breakthroughs for patients and create value for shareholders and other stakeholders. The company is committed to strategically capitalizing on growth opportunities, not only by advancing its product pipeline and maximizing the value of the existing products but also through various business development activities. R&D expenses increased USD 4.4 billion in 2021 as compared to 2020, primarily due to the charge for acquired IPR&D related to our acquisition of Trillium, a net increase in charges for upfront, milestone payments on collaboration and licensing arrangements, and increased investments across multiple therapeutic areas, including additional spending related to the development of the oral COVID-19 treatment program.

Roche held the leading position in the HPAPI market due to its robust product portfolio and wide geographic reach. Its pharmaceuticals segment develops and launches APIs. To remain competitive and further strengthen its market position, the company adopts inorganic growth strategies such as acquisitions. In the past three years, the company has acquired three other players to strengthen its position in the market. The company also focuses on maintaining and enhancing its production capabilities; for example, the company entered licensing agreement with Sarepta Therapeutics to improve the lives of patients living with Duchenne muscular dystrophy. Also, the company entered licensing agreement with Sarepta Therapeutics to improve the lives of patients living with Duchenne muscular dystrophy. Such deals help the company remain competitive in the dynamic global HPAPIs market

R&D Capabilities: To remain competitive and further strengthen its market position, the company adopts inorganic growth strategies, such as an acquisition. Sales in the Pharmaceuticals Division in 2021 were USD 31.91 billion, an increase of 3% at CER as compared to 2020. New product sales were more than compensated for biosimilar competition to MabThera/Rituxan, Herceptin, and Avastin. The sales growth was driven by growing demand for new medicines, including Hemlibra, Ocrevus, Tecentriq, Evrysdi, Phesgo, and Ronapreve. In the second half of the year, the biosimilar impact was slowing down as expected. To remain competitive and further strengthen its market position, the company adopts inorganic growth strategies, such as an acquisition. In the past three years, La Roche has acquired many other players to strengthen its position in the market. The company also focuses on maintaining and enhancing its production capabilities; such initiatives help the company to maintain its market share and remain competitive in the dynamic global HPAPI market.

Related Reports:

High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region - Global forecast to 2027

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]

Report Code
PH 4897
RI Published ON
5/17/2022
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the High Potency APIs Market/HPAPI Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
REQUEST A FREE WORKSHOP
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2022 MarketsandMarkets Research Private Ltd. All rights reserved